Trial Profile
Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with Acute on Chronic Liver Failure
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Liver failure
- Focus Adverse reactions
- Sponsors Promethera Biosciences
- 13 Oct 2020 Status changed from active, no longer recruiting to completed.
- 02 Oct 2020 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 13 Sep 2020 This trial has been completed in France (Date of the global end of the trial: 21 Aug 2020).